New AMD dosing device used at Newmedica

An NHS patient has become the first person in a real-world setting to undergo a procedure with the OcuClick, a device that ensures the precise dosing of Eylea 8mg for wet age-related macular degeneration (AMD).

Performed by ophthalmologist and AMD expert, Professor Richard Gale, the procedure took place at Newmedica Lincolnshire.

“This fully approved device not only ensures the correct dosage every time, but also reduces the time patients spend in the injection suite,” explained Professor Gale.

Gale highlighted that the new device would enable more patients to be treated for wet AMD in the same amount of time.

He said: “This is important because around 40,000 people are diagnosed with wet AMD every year in the UK, and patients require regular injections. The ability to deliver all the injections required is a challenge.”

“This innovation provides a more efficient treatment method and so is good news for the NHS, costing them no more money, while potentially enabling more patients to be seen,” he added.

Traditionally, wet AMD treatments have involved drawing medication from a glass vial and manually measuring the dosage.

The pre-filled OcuClick syringe contains Eylea 8mg, which is also used to treat diabetic macular oedema.

Gale confirmed that he is now using the OcuClick for all wet AMD patients being treated with Eylea 8mg.